Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


South Korea Resumes A/H1N1 Vaccine Talks With GSK, Novartis, Sanofi-Aventis, Baxter, CSL

This article was originally published in PharmAsia News

Executive Summary

SEOUL - One month after South Korea's Ministry for Health, Welfare and Family Affairs failed to select a company to provide A/H1N1 vaccines at what it considered a "reasonable price," the ministry reopened talks with Baxter International, GlaxoSmithKline, Novartis, CSL of Australia and Sanofi-Aventis to calm mounting public pressure to secure the vaccines

You may also be interested in...

Korea Moves To Cover A/H1N1 Test With National Health Insurance

SEOUL - Alarmed over the deaths of two South Koreans over the weekend infected with the A/H1N1 virus and over the rising number of people who have fallen victim to the pandemic, the government is moving to have the H1N1 test covered by the national health insurance system

South Korea's Green Cross Begins "Test Production" of Flu Vaccine

SEOUL - South Korean pharmaceutical company Green Cross recently started "test production" of its own A/H1N1 flu vaccine, after receiving a virus strain from the UK's National Institution for Biological Standards and Control and from the Centers for Disease Control and Prevention of the U.S

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts